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Abstract
Purpose: Compared to other subtypes of epithelial ovarian cancer, clear cell carcinoma of the ovary bears an
ominous reputation for chemotherapy resistance, increased relapse rate, and diminished survival. Among patients
with distinct histopathologic subtypes, molecular analyses have identified a variety of known drivers of the
malignant behavior, and depict a striking heterogeneity.
Methods: A patient with rapidly metastatic CCCO that was refractory to taxane, platinum, pemetrexed, and
bevacizumab-based strategies underwent molecular profiling which disclosed dual MAPK and PI3K/AKT/mTOR
pathway mutations.
Results: Combined targeted therapy with trametinib and metformin resulted in a dramatic disease regression
without toxicity.
Conclusion: The case highlights the utility of precision medicine combining individual molecular diagnosis with
rational therapeutic intervention with targeted agents.
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Background
Clear cell carcinoma of the ovary (CCCO) represents a dis-
tinct histopathologic subtype [1] comprising 3.7–12.1 % of
epithelial ovarian carcinoma (EOC). In general, CCCO has
earned notoriety for being a particular challenge for man-
agement characterized by higher recurrence rates among
patients with early stage disease, poor responsiveness to
chemotherapy, especially platinum [2–7], de novo drug
resistance, and inferior survival compared to other subtypes
of EOC [8]. In light of these characteristics, many investiga-
tors have opined that CCCO deserves a unique treatment
strategy as a distinct disease entity. Nevertheless, current
guidelines recommend similar adjuvant treatment regimens
as used for other EOC histologies.
Molecular studies have demonstrated differences in the
genomic characteristics of CCCO compared to other
histological subtypes of EOC and suggest it may be amen-
able to different therapeutic approaches. In addition, indi-
vidual differences have been observed between patients
despite the common clear cell histology. In a recent study
of 69 CCCO’s patients analyzed by next generation
sequencing (NGS), PIK3CA was the most common muta-
tion (52 vs. 8 % in all EOCs and 14 % in mixed CCCO’s),
followed by TP53 (16 %) and KRAS (11 %). Mutations in
FBXW7 (10 %), APC (7 %), and ATM (6 %) were observed
at a higher rate than in other EOCs. Among 33 with
PIK3CA mutations, 4 (12 %) had co-existing mutations
in KRAS and 2 (6 %) had TP53 mutations while 70 %
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(23/33) over-expressed cMET and 12 % had a loss of
PTEN [9]. Relative cyclin E mRNA expression is often
significantly higher in the CCCO’s [10], Hepatocyte nu-
clear factor-1 beta has also been identified as a molecu-
lar marker and touted as a possible molecular target for
intervention [11].
We describe the application of DNA sequencing to
identify known molecular drivers of malignancy in a pa-
tient with chemotherapy-refractory metastatic CCCO.
The use of off-label, NGS-directed therapy led to mean-
ingful disease regression and control.
Case presentation
The patient is a 40-year old woman with a history of
endometriosis and infertility. In the spring of 2014 she
developed pelvic pain. Trans-vaginal ultrasound revealed
endometriosis and a complex cystic mass of the right
ovary consistent with possible malignancy. The CA-125
was 32. She was taken to the operating room for a lap-
aroscopic right ovarian cystectomy. Based on visible
tumor within the ovary at surgery, the operation was
converted to a staging laparotomy with traditional cytor-
eductive surgery with total abdominal hysterectomy,
bilateral salpingo-oophorectomy, bilateral pelvic and
para-aortic lymph node dissection, peritoneal biopsies,
and peritoneal washings. No residual disease remained
after surgery. Pathology disclosed clear cell carcinoma of
the right ovary. Examination of the uterus revealed
adenomyosis and endometriosis with focal clear cell car-
cinoma near the parametrial margin; 13 pelvic and para-
aortic lymph nodes from the right and 15 from the left
side showed no evidence of metastatic disease. The
omentum contained a small focus of malignant cells,
however the remainder of samples from the pelvis, para-
colic gutters, and the undersides of the diaphragms
revealed no cancer. She was staged as having FIGO stage
IIIA2 clear cell carcinoma of the ovary.
Beginning in June 2014 she was treated with post-
operative, adjuvant, dose dense paclitaxel and carbopla-
tin x 6 cycles, which were completed in October 2014. A
post-treatment PET scan in October 2014 revealed meta-
static progression with hypermetabolic metastatic dis-
ease in the liver and multiple sites of hypermetabolic
lymphadenopathy throughout the pelvis including the
vaginal cuff. Chemotherapy utilizing pemetrexed and
bevacizumab was administered the following week for
three treatment cycles until December 2014. In January
2015, another PET scan disclosed new hypermetabolic
disease in the left lung measuring 8 mm, additional new
hypermetabolic lymph nodes in the left iliac chain, and
progression in the liver with multiple metastases.
Germline BRCA1 and two testing at Myriad Genetics
was negative. Comprehensive genomic analysis of the pri-
mary ovarian tumor tissue was arranged by the Clearity
Foundation (www.clearityfoundation.org) and included
NGS analysis at Foundation Medicine, Inc. (Cambridge,
MA) to identify actionable genomic alterations in key on-
cogenes and tumor suppressor genes (exonic regions of
315 genes). This analysis revealed KRAS, PIK3CA, and
TERT mutations (Table 1).
The MEK inhibitor, trametinib (2 mg daily) and met-
formin (850 mg q12hr) which activates AMPK and also
inhibits the AKT-mTOR pathway, were instituted
3 weeks later. The patient was not a participant on any
active research protocol. Trametinib was obtained
through Tripler Medical Center which does not restrict
the use of off-label medicine or require insurance pre-
authorization. The selection of metformin in lieu of a
standard mTOR inhibitor, such as everolimus, was made
because of the failure of the phase I effort to define a
safe combination of trametinib and everolimus for phase
II testing [12].
At the start of treatment, the CA125 was 936. After
2 months of treatment, the CA125 fell to 69. A follow-
up PET scan at that time revealed complete resolution of
the metastatic disease in the liver and lung, fading and
nearly complete disappearance of the vaginal cuff lesion,
disappearance of pelvic adenopathy, and a new hyper-
metabolic focus at the aortic bifurcation (Fig. 1). The pa-
tient experienced no side effects or clinical toxicities
from the treatment. Hypoglycemia did not occur. The
response lasted 5 months before progressive disease en-
sued. Repeat tissue sampling to determine the mechan-
ism of resistance is under consideration.
Conclusions
This case of clear cell carcinoma of the ovary depicts the
notorious problems of chemotherapy resistance and
early relapse. In just 6 months, her outlook evolved from
a hope for cure to imminent death with tumor growth
on both adjuvant taxane-platinum and pemetrexed-
bevacizumab combinations. Her cancer possesses a
PIK3CA mutation, a finding in 34 % of CCCO (http://
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cancer.sanger.ac.uk/cosmic/search?q=PIK3CA+ovarian),
causing upregulation of the AKT pathway, which is fre-
quently associated with de novo resistance to platinum
combinations [13]. In the sister disease, clear cell carcin-
oma of the kidney, molecular aberrations in the AKT
pathway have also been reported in 20 % of patients
[14], and have been successfully treated with MTOR in-
hibitors. A KRAS mutation was also identified in this pa-
tient’s cancer, a finding present in 14 % of CCCO
patients [15]. These mutations suggested a dual strategy
of MEK and AKT pathway inhibition.
Derangement in the MAP kinase pathway plays a cen-
tral role in the proliferation and progression of many
cancers. Trametinib is an FDA-approved allosteric in-
hibitor of MEK1 and MEK2 capable of inhibiting cancers
with KRAS mutations by producing downstream block-
ade. Metformin has been shown to alter AMPK, a
protein kinase that directly and indirectly regulates
mTOR signaling via phosphorylation of Raptor and
TSC2, respectively. Proof of concept studies of metformin
have been reported, including regression of breast [16]
and pancreatic cancers [17]. This approach, employing
simultaneous blockade of AKT and MAPK pathways, has
produced durable responses [18, 19]. In patients with
KRAS-mutant ovarian cancer, MEK and PI3K inhibitors
have provided response rates of 50–75 % [20–22]. Add-
itionally, KRAS G12V mutation, which was present in this
case, is a marker for responsiveness to MEK inhibition in
patients with low grade serous ovarian cancer [23]. Even
though efforts to combine MEK inhibitors with PI3K/
AKT/m-TOR inhibitors have thus far been plagued by the
inability to identify a tolerable, safe dose for phase II
testing [12], remarkably this patient experienced no toxic
effects from the combination of trametinib and
metformin.
This patient’s success validates the strategy of dual
pathway inhibition as an approach to cancer with muta-
tions in both the MAPK and AKT pathways. It high-
lights the potential safety of combining metformin and
trametinib. This case also demonstrates the utility of
linking molecular diagnosis with therapeutic decision-
making for patients with advanced, chemotherapy-
refractory disease. As such, the use of precision
medicine to provide driver-drug strategies offers hope
for patients with CCCO and other malignancies with
this molecular etiology. This process is a promising, ra-
tional method for replacing the genomically-naïve
approach to treatment that still dominates the standard
of care for the entire spectrum of epithelial ovarian
cancer.
This patient was fortunate to gain access to a drug that
is usually unavailable to ovarian cancer patients due to
strict payor policies that follow the drug license to the
letter. However, over-zealous regulatory behavior and
wholesale restriction of physician prescribing can de-
prive patients of life-saving medicines. In an era when
molecular insights have theranostic value that can
outperform the limitations of standard therapeutic op-
tions, molecular tumor boards to determine the appro-
priateness of novel therapies could help patients access
breakthrough approaches whose availability is hampered
by the regulatory mechanism, but which are nevertheless
readily available and tailor made for their individual
cancers.
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Fig. 1 Comparison of baseline (left) and post-treatment (right) PET scans (3D MIP images)
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